Cybin Inc. has concluded its fiscal year with several key business developments and a detailed annual report. Despite not generating revenue, the company faced a net loss of $78,080,000, with a basic loss per share of $0.25. Notable achievements include the acquisition of Small Pharma Inc., which expanded Cybin's intellectual property with 17 active patent families. The company also established a new equity program and entered into a purchase agreement with Lincoln Park Capital Fund, LLC, potentially raising up to US$65,000,000 through common share sales. Additionally, Cybin conducted multiple capital-raising efforts, including public offerings and a private placement. The company has engaged in licensing agreements, notably with Mindset Pharma Inc., to bolster its research and development. Cybin's strategy focuses on advancing psychedelic-inspired therapeutics and expanding its intellectual property through acquisitions and licensing. The company complies with regulatory frameworks across several jurisdictions and has received approvals for clinical trials. Despite the competitive market and inherent risks of the psychedelic pharmaceutical industry, Cybin continues to progress towards its business objectives.

Cybin Inc. has concluded its fiscal year with several key business developments and a detailed annual report. Despite not generating revenue, the company faced a net loss of $78,080,000, with a basic loss per share of $0.25. Notable achievements include the acquisition of Small Pharma Inc., which expanded Cybin's intellectual property with 17 active patent families. The company also established a new equity program and entered into a purchase agreement with Lincoln Park Capital Fund, LLC, potentially raising up to US$65,000,000 through common share sales. Additionally, Cybin conducted multiple capital-raising efforts, including public offerings and a private placement. The company has engaged in licensing agreements, notably with Mindset Pharma Inc., to bolster its research and development. Cybin's strategy focuses on advancing psychedelic-inspired therapeutics and expanding its intellectual property through acquisitions and licensing. The company complies with regulatory frameworks across several jurisdictions and has received approvals for clinical trials. Despite the competitive market and inherent risks of the psychedelic pharmaceutical industry, Cybin continues to progress towards its business objectives.